Ambu A/S Class B (AMBFF)
OTHER OTC:AMBFF
Earnings Data
Report Date
May 06, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.09Last Year’s EPS
0.11Same Quarter Last Year
Moderate Buy
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call highlights strong, broad-based momentum in the core Endoscopy business (Respiratory and Urology) with new product launches, strategy rollout and underlying adjusted margins above 15%. However, near-term results were weighed down by external headwinds — significant tariff costs, USD/DKK depreciation (FX drag), a reported drop in EBIT margin and low Q1 free cash flow. Management is maintaining full-year guidance and expects tariffs to ease in H2 as Mexico ramp-up continues, suggesting confidence in the underlying operational recovery.Company Guidance
Strong Overall Revenue Growth
Total revenue grew 8.6% year-over-year for Q1; Endoscopy Solutions represented 63% of total revenue and grew 14.4% in the quarter.
Robust Endoscopy Momentum — Respiratory
Respiratory organic growth of 8.3% in Q1 vs a very strong comparable last year; management expects acceleration in respiratory driven by aScope 4/5 adoption, SureSight adoption and cross-selling.
Urology / ENT / GI Outperformance
Urology, ENT and GI segment grew 21% year-over-year in Q1 driven by continued penetration of aScope 4 and growing uptake of aScope 5 Cysto/Uretero.
Product and Strategy Launches
Launched the ZOOM AHEAD growth strategy and new products including SureSight Mobile (video laryngoscope handheld) and aScope 4 Cysto in China (locally manufactured); Recircle recycling program expanded to 50 hospitals and >100 clinical departments and now includes SureSight blades.
Underlying Profitability (adjusted)
Reported EBIT before special items was DKK 164 million (10.5% EBIT margin). After adjusting for tariffs and FX headwinds management reports an underlying adjusted EBIT margin above 15%, aligned with margin expansion plan.
Healthy Gross Margin and Manufacturing Leverage
Gross margin at 60.8% — lower than last year's Q1 but higher than last financial year's average — benefitting from higher endoscopy mix, price governance and improved utilization (notably Mexico factory).
Maintained Full-Year Guidance
Company maintained full-year organic growth guidance of 10%–13% (Endoscopy Solutions +15%) and EBIT margin guidance of 12%–14% despite tariffs and FX headwinds.
Investment in Software and AI
Progress on EndoIntelligence with improved documentation, EMR integration, and AI bronchoscopy navigation training; R&D and CapEx increasing to support software and hardware innovation.
AMBFF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
AMBFF Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 04, 2026 | $13.20 | $13.90 | +5.30% |
Nov 05, 2025 | $14.48 | $14.48 | 0.00% |
Aug 22, 2025 | $14.64 | $15.23 | +4.08% |
May 07, 2025 | $18.31 | $18.31 | 0.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Ambu A/S Class B (AMBFF) report earnings?
Ambu A/S Class B (AMBFF) is schdueled to report earning on May 06, 2026, TBA (Confirmed).
What is Ambu A/S Class B (AMBFF) earnings time?
Ambu A/S Class B (AMBFF) earnings time is at May 06, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AMBFF EPS forecast?
AMBFF EPS forecast for the fiscal quarter 2026 (Q2) is 0.09.